RU2019137430A3 - - Google Patents

Download PDF

Info

Publication number
RU2019137430A3
RU2019137430A3 RU2019137430A RU2019137430A RU2019137430A3 RU 2019137430 A3 RU2019137430 A3 RU 2019137430A3 RU 2019137430 A RU2019137430 A RU 2019137430A RU 2019137430 A RU2019137430 A RU 2019137430A RU 2019137430 A3 RU2019137430 A3 RU 2019137430A3
Authority
RU
Russia
Application number
RU2019137430A
Other languages
Russian (ru)
Other versions
RU2019137430A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019137430A publication Critical patent/RU2019137430A/ru
Publication of RU2019137430A3 publication Critical patent/RU2019137430A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2019137430A 2017-05-24 2018-05-22 Нейротрофины для применения в лечении тугоухости RU2019137430A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17172659.9A EP3406259A1 (en) 2017-05-24 2017-05-24 Neurotrophins for use in the treatment of hearing loss
EP17172659.9 2017-05-24
PCT/EP2018/063310 WO2018215414A1 (en) 2017-05-24 2018-05-22 Neurotrophins for use in the treatment of hearing loss

Publications (2)

Publication Number Publication Date
RU2019137430A RU2019137430A (ru) 2021-06-24
RU2019137430A3 true RU2019137430A3 (https=) 2021-08-30

Family

ID=58772736

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019137430A RU2019137430A (ru) 2017-05-24 2018-05-22 Нейротрофины для применения в лечении тугоухости

Country Status (11)

Country Link
US (1) US20200155647A1 (https=)
EP (2) EP3406259A1 (https=)
JP (1) JP2020520956A (https=)
KR (1) KR20200011951A (https=)
CN (1) CN110691607A (https=)
AU (1) AU2018274589A1 (https=)
BR (1) BR112019024504A2 (https=)
CA (1) CA3062744A1 (https=)
IL (1) IL270701A (https=)
RU (1) RU2019137430A (https=)
WO (1) WO2018215414A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021151013A1 (en) * 2020-01-24 2021-07-29 Otonomy, Inc. Growth factor formulation for condition associated with otic event
WO2022221351A1 (en) * 2021-04-13 2022-10-20 Dompé Farmaceutici S.P.A. Treatment of neuropathic corneal pain with ngf
EP4452267B1 (en) * 2021-12-23 2025-04-23 Cilcare Dev 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases
EP4316505A1 (en) * 2022-08-05 2024-02-07 Dompé farmaceutici S.p.a. Intranasal administration of ngf for the treatment of sensorineural hearing loss
KR102851394B1 (ko) * 2022-11-11 2025-09-04 단국대학교 천안캠퍼스 산학협력단 광반응성 하이드로젤을 이용한 분화유도인자 탑재 나노캡슐
EP4501346A1 (en) * 2023-08-04 2025-02-05 Dompe' Farmaceutici S.P.A. Method for the prevention of hearing loss induced by a platinum-based chemotherapy drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225282B1 (en) * 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
US7700111B2 (en) * 2002-01-17 2010-04-20 The Regents Of The University Of Michigan Auditory nerve protection and re-growth
WO2009062149A1 (en) * 2007-11-08 2009-05-14 Creighton University Methods for maintaining inner ear neurons
EP2907521B1 (en) 2011-12-19 2017-11-22 Wacker Chemie AG Novel prongf mutants and uses thereof in the production of beta-ngf
KR20180037994A (ko) * 2015-07-28 2018-04-13 오토노미, 인코포레이티드 TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법
US10066229B2 (en) * 2015-07-28 2018-09-04 Otonomy, Inc. Treatment using truncated Trk B and Trk C antagonists

Also Published As

Publication number Publication date
EP3406259A1 (en) 2018-11-28
CN110691607A (zh) 2020-01-14
BR112019024504A2 (pt) 2020-06-23
WO2018215414A1 (en) 2018-11-29
CA3062744A1 (en) 2018-11-29
US20200155647A1 (en) 2020-05-21
JP2020520956A (ja) 2020-07-16
EP3630159A1 (en) 2020-04-08
RU2019137430A (ru) 2021-06-24
AU2018274589A1 (en) 2019-11-28
IL270701A (en) 2020-01-30
KR20200011951A (ko) 2020-02-04

Similar Documents

Publication Publication Date Title
BR122021024395A2 (https=)
BR122021000189A2 (https=)
BR112019008823A2 (https=)
BR112020006084A8 (https=)
BR122022025811B8 (https=)
BR202018014992U2 (https=)
BR122021023687A2 (https=)
BR122021014832A2 (https=)
BR122022003521A2 (https=)
BR112020008820A2 (https=)
BR202017025154U2 (https=)
BR102017023327A2 (https=)
BR202017021228U2 (https=)
BR202017020981U2 (https=)
BR202017017068U2 (https=)
BR202017016984U2 (https=)
BR202017016924U2 (https=)
BR102017015495A2 (https=)
BR102017015250A2 (https=)
BR102017014430A2 (https=)
BR202017012548U2 (https=)
BR202017011220U2 (https=)
BR202017010814U2 (https=)
BR202017010373U2 (https=)
BR202017009870U2 (https=)